Skip to main content
Top
Published in: Endocrine 3/2020

01-06-2020 | Coronavirus | Meta- Analysis

Worldwide ACE (I/D) polymorphism may affect COVID-19 recovery rate: an ecological meta-regression

Authors: Naser Hatami, Salma Ahi, Alireza Sadeghinikoo, Mahdi Foroughian, Farshid Javdani, Navid Kalani, Mostafa Fereydoni, Pouyan Keshavarz, Ava hosseini

Published in: Endocrine | Issue 3/2020

Login to get access

Abstract

With the emergence of the Novel Coronavirus (2019-nCoV), researchers worldwide have started detecting the probable pathogenesis of the disease. The renin–angiotensin system (RAS) and angiotensin-converting enzymes have received a good deal of attention as possible pathways involved in 2019-nCoV pathogenesis. As the experiments seeking to find potential medications acting on these pathways are being conducted in the early phases, having an ecological worldview on the relationship between the prevalence of COVID-19 disease and the genetic differences in the genes involved in the RAS system could be valuable for the field. In this regard, we conducted a meta-analysis study of the prevalence of ACE (I/D) genotype in countries most affected by the COVID-19. In the meta-analysis, 48,758 healthy subjects from 30 different countries were evaluated in 116 studies, using the Comprehensive Meta-analysis software. The I/D allele frequency ratio was pooled by a random-effect model. The COVID-19 prevalence data of death and recovery rates were evaluated as the latitudes for the meta-regression analysis. Our results demonstrated that with the increase of the I/D allele frequency ratio, the recovery rate significantly increased (point estimate: 0.48, CI 95%: 0.05–0.91, p = 0.027). However, there was no significant difference in the case of death rate (point estimate: 1.74, CI 95%: 4.5–1.04, p = 0.22). This ecological perspective coupled with many limitations does not provide a direct clinical relevance between the COVID-19 and RAS system, but it shows potential pathophysiological associations. Our results raise concerns about ethnic and genetic differences that could affect the effectiveness of the currently investigated RAS-associated medications in different regions.
Appendix
Available only for authorised users
Literature
1.
go back to reference S.R. Weiss, S. Navas-Martin, Coronavirus pathogenesis and the emerging pathogen severe acute respiratory syndrome coronavirus. Microbiol. Mol. Biol. Rev. 69(4), 635–664 (2005)CrossRef S.R. Weiss, S. Navas-Martin, Coronavirus pathogenesis and the emerging pathogen severe acute respiratory syndrome coronavirus. Microbiol. Mol. Biol. Rev. 69(4), 635–664 (2005)CrossRef
2.
go back to reference Lai. M. C, Coronaviridae. Fields virology 1, 1305–1318 (2007) Lai. M. C, Coronaviridae. Fields virology 1, 1305–1318 (2007)
3.
go back to reference B.A. Wevers, L. van der Hoek, Recently discovered human coronaviruses. Clin. Lab. Med. 29(4), 715–724 (2009)CrossRef B.A. Wevers, L. van der Hoek, Recently discovered human coronaviruses. Clin. Lab. Med. 29(4), 715–724 (2009)CrossRef
4.
go back to reference D.A. Tyrrell, M.L. Bynoe, Cultivation of a novel type of common-cold virus in organ cultures. Br. Med. J. 1, 1467–1470 (1965)CrossRef D.A. Tyrrell, M.L. Bynoe, Cultivation of a novel type of common-cold virus in organ cultures. Br. Med. J. 1, 1467–1470 (1965)CrossRef
5.
go back to reference M.L. Sun, J.M. Yang, Y.P. Sun, G.H. Su, Inhibitors of RAS Might Be a Good Choice for the therapy of COVID-19 Pneumonia. Chin. J. Tuberc. Respir. Dis. 43(Feb), E014 (2020) M.L. Sun, J.M. Yang, Y.P. Sun, G.H. Su, Inhibitors of RAS Might Be a Good Choice for the therapy of COVID-19 Pneumonia. Chin. J. Tuberc. Respir. Dis. 43(Feb), E014 (2020)
6.
go back to reference Y.B. Saab, P.R. Gard, A.D. Overall, The geographic distribution of the ACE II genotype: a novel finding. Genet. Res. 89(4), 259–267 (2007)CrossRef Y.B. Saab, P.R. Gard, A.D. Overall, The geographic distribution of the ACE II genotype: a novel finding. Genet. Res. 89(4), 259–267 (2007)CrossRef
7.
go back to reference E. Livingston, K. Bucher, Coronavirus disease 2019 (COVID-19) in Italy. JAMA. 323(14), 1335 (2020)CrossRef E. Livingston, K. Bucher, Coronavirus disease 2019 (COVID-19) in Italy. JAMA. 323(14), 1335 (2020)CrossRef
8.
go back to reference K. Wang, Y. Li, C. Dai, K. Wang, J. Yu, Y. Tan, W. Zhang, X.F. Yu, Characterization of the relationship between APOBEC3B deletion and ACE Alu insertion. PloS one. 8(5), e64809 (2013)CrossRef K. Wang, Y. Li, C. Dai, K. Wang, J. Yu, Y. Tan, W. Zhang, X.F. Yu, Characterization of the relationship between APOBEC3B deletion and ACE Alu insertion. PloS one. 8(5), e64809 (2013)CrossRef
10.
go back to reference X. Li, X. Sun, L. Jin, F. Xue, Worldwide spatial genetic structure of angiotensin-converting enzyme gene: a new evolutionary ecological evidence for the thrifty genotype hypothesis. Eur. J. Hum. Genet. 19(9), 1002–1008 (2011)CrossRef X. Li, X. Sun, L. Jin, F. Xue, Worldwide spatial genetic structure of angiotensin-converting enzyme gene: a new evolutionary ecological evidence for the thrifty genotype hypothesis. Eur. J. Hum. Genet. 19(9), 1002–1008 (2011)CrossRef
11.
go back to reference F. Wu, S. Zhao, B. Yu, Y.M. Chen, W. Wang, Z.G. Song, Y. Hu, Z.W. Tao, J.H. Tian, Y.Y. Pei, M.L. Yuan, A new coronavirus associated with human respiratory disease in China. Nature. 579(7798), 265–269 (2020)CrossRef F. Wu, S. Zhao, B. Yu, Y.M. Chen, W. Wang, Z.G. Song, Y. Hu, Z.W. Tao, J.H. Tian, Y.Y. Pei, M.L. Yuan, A new coronavirus associated with human respiratory disease in China. Nature. 579(7798), 265–269 (2020)CrossRef
13.
go back to reference X.H. Fan, Y.B. Wang, H. Wang, K. Sun, W.L. Zhang, X.D. Song, J.Z. Cheng, H.Y. Wu, X.L. Zhou, R.T. Hui, Polymorphisms of angiotensin-converting enzyme (ACE) and ACE2 are not associated with orthostatic blood pressure dysregulation in hypertensive patients. Acta Pharmacol. Sinica 30(9), 1237–1244 (2009)CrossRef X.H. Fan, Y.B. Wang, H. Wang, K. Sun, W.L. Zhang, X.D. Song, J.Z. Cheng, H.Y. Wu, X.L. Zhou, R.T. Hui, Polymorphisms of angiotensin-converting enzyme (ACE) and ACE2 are not associated with orthostatic blood pressure dysregulation in hypertensive patients. Acta Pharmacol. Sinica 30(9), 1237–1244 (2009)CrossRef
14.
go back to reference Y. Cao, L. Li, Z. Feng, S. Wan, P. Huang, X. Sun, F. Wen, X. Huang, G. Ning, W. Wang, Comparative genetic analysis of the novel coronavirus (2019-nCoV/SARS-CoV-2) receptor ACE2 in different populations. Cell Discov. 6(1), 1–4 (2020)CrossRef Y. Cao, L. Li, Z. Feng, S. Wan, P. Huang, X. Sun, F. Wen, X. Huang, G. Ning, W. Wang, Comparative genetic analysis of the novel coronavirus (2019-nCoV/SARS-CoV-2) receptor ACE2 in different populations. Cell Discov. 6(1), 1–4 (2020)CrossRef
16.
go back to reference R.P. Marshall, S. Webb, G.J. Bellingan, H.E. Montgomery, B. Chaudhari, R.J. McAnulty, S.E. Humphries, M.R. Hill, G.J. Laurent, Angiotensin converting enzyme insertion/deletion polymorphism is associated with susceptibility and outcome in acute respiratory distress syndrome. Am. J Respir. Crit. Care Med. 166(5), 646–650 (2002)CrossRef R.P. Marshall, S. Webb, G.J. Bellingan, H.E. Montgomery, B. Chaudhari, R.J. McAnulty, S.E. Humphries, M.R. Hill, G.J. Laurent, Angiotensin converting enzyme insertion/deletion polymorphism is associated with susceptibility and outcome in acute respiratory distress syndrome. Am. J Respir. Crit. Care Med. 166(5), 646–650 (2002)CrossRef
17.
go back to reference M. Onizuka, M. Kasai, T. Oba, Y. Atsuta, S. Terakura, R. Suzuki, K. Kitaori, K. Miyamura, T. Hotta, Y. Kodera, Increased frequency of the angiotensin-converting enzyme gene D-allele is associated with noninfectious pulmonary dysfunction following allogeneic stem cell transplant. Bone Marrow Transplant. 36(7), 617–620 (2005)CrossRef M. Onizuka, M. Kasai, T. Oba, Y. Atsuta, S. Terakura, R. Suzuki, K. Kitaori, K. Miyamura, T. Hotta, Y. Kodera, Increased frequency of the angiotensin-converting enzyme gene D-allele is associated with noninfectious pulmonary dysfunction following allogeneic stem cell transplant. Bone Marrow Transplant. 36(7), 617–620 (2005)CrossRef
Metadata
Title
Worldwide ACE (I/D) polymorphism may affect COVID-19 recovery rate: an ecological meta-regression
Authors
Naser Hatami
Salma Ahi
Alireza Sadeghinikoo
Mahdi Foroughian
Farshid Javdani
Navid Kalani
Mostafa Fereydoni
Pouyan Keshavarz
Ava hosseini
Publication date
01-06-2020
Publisher
Springer US
Published in
Endocrine / Issue 3/2020
Print ISSN: 1355-008X
Electronic ISSN: 1559-0100
DOI
https://doi.org/10.1007/s12020-020-02381-7

Other articles of this Issue 3/2020

Endocrine 3/2020 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.